PT  - JOURNAL ARTICLE
AU  - Corral-Gudino, Luis
AU  - Bahamonde, Alberto
AU  - Arnaiz-Revillas, Francisco
AU  - Gómez-Barquero, Julia
AU  - Abadía-Otero, Jesica
AU  - García-Ibarbia, Carmen
AU  - Mora, Víctor
AU  - Cerezo-Hernández, Ana
AU  - Hernández, José L.
AU  - López-Muñíz, Graciela
AU  - Hernández-Blanco, Fernando
AU  - Cifrián, Jose M.
AU  - Olmos, Jose M.
AU  - Carrascosa, Miguel
AU  - Nieto, Luis
AU  - Fariñas, María Carmen
AU  - Riancho, José A.
AU  - ,
AU  - Bahamonde, Alberto
AU  - Hernández-Blanco, Fernando
AU  - Buelta-González, Cristina
AU  - Marcos-Martínez, Luis A.
AU  - Martínez-Vidal, Ana I.
AU  - Dosantos-Gallego, Pilar R.l
AU  - Pérez-Sagredo, Jesús
AU  - Sandomingo-Freire, Silvia
AU  - Muñumer-Blázquez, Rebeca
AU  - Paredes-Mogollo, Antonio
AU  - Brague-Allegue, Elena
AU  - Carrascosa, Miguel
AU  - García-Rivero, Juan L.
AU  - Riancho, José A.
AU  - Olmos, José M.
AU  - Fariñas, Carmen
AU  - Cifrian, José M.
AU  - García-Ibarbia, Carmen
AU  - Hernández, Jose L.
AU  - Arnaiz-Revillas, Francisco
AU  - Mora, Victor
AU  - Nieto, Sara
AU  - Ruiz-Cubillán, Juan
AU  - Bermúdez, Arancha
AU  - Pardo, Javier
AU  - Amado, Carlos
AU  - Insunza, Andrés
AU  - Gil, Aritz
AU  - Diaz-Terán, Teresa
AU  - Fayos, Marina
AU  - Zabaleta, Miguel A.
AU  - Parra, Juan J.
AU  - Corral-Gudino, Luis
AU  - Gómez-Barquero, Julia
AU  - Abadía-Otero, Jesica
AU  - Cerezo-Hernández, Ana
AU  - López-Muñíz, Graciela
AU  - Ruíz-de-Temiño-de-la-Peña, Angela
AU  - Arroyo-Domingo, C. Ainhoa
AU  - Mena-Martín, Javier
AU  - Miramontes-González, Pablo
AU  - Jiménez-Masa, Ana E
AU  - Pastor-Mancisidor, Luis
AU  - Álvaro-de-Castro, Tanía M
AU  - Pérez-Panizo, María Cruz
AU  - Ruíz-Albi, Tomás
AU  - de-la-Colina-Rojo, C Gema
AU  - Andrés-Calvo, María
AU  - Crespo-Sedano, Andrea
AU  - Morejón-Huerta, Begoña
AU  - Briongos-Figuero, Laisa S.
AU  - Frutos-Arriba, Julio F
AU  - Pagán-Buzo, Javier
AU  - Gabella-Martín, Miriam
AU  - Cobos-Siles, Marta
AU  - Gómez-García, Ana
AU  - Nieto, Luis
TI  - GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia
AID  - 10.1101/2020.06.17.20133579
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.17.20133579
4099  - http://medrxiv.org/content/early/2020/06/18/2020.06.17.20133579.short
4100  - http://medrxiv.org/content/early/2020/06/18/2020.06.17.20133579.full
AB  - Background We aimed to determine whether a 6-day course of intravenous methylprednisolone (MP) improves outcome in patients with SARS CoV-2 infection at risk of developing Acute Respiratory Distress Syndrome (ARDS).Methods Multicentric, partially randomized, preference, open-label trial, including adults with COVID-19 pneumonia, impaired gas exchange and biochemical evidence of hyper-inflammation. Patients were assigned to standard of care (SOC), or SOC plus intravenous MP [40mg/12h 3 days, then 20mg/12h 3 days]. The primary endpoint was a composite of death, admission to the intensive care unit (ICU) or requirement of non-invasive ventilation (NIV).Results We analyzed 85 patients (34, randomized to MP; 22, assigned to MP by clinician’s preference; 29, control group). Patients’ age (mean 68±12 yr) was related to outcome. The use of MP was associated with a reduced risk of the composite endpoint in the intention-to-treat, age-stratified analysis (combined risk ratio -RR-0.55 [95% CI 0.33-0.91]; p=0.024). In the per-protocol analysis, RR was 0.11 (0.01-0.83) in patients aged 72 yr or less, 0.61 (0.32-1.17) in those over 72 yr, and 0.37 (0.19-0.74, p=0.0037) in the whole group after age-adjustment by stratification. The decrease in C-reactive protein levels was more pronounced in the MP group (p=0.0003). Hyperglycemia was more frequent in the MP group.Conclusions A short course of MP had a beneficial effect on the clinical outcome of severe COVID-19 pneumonia, decreasing the risk of the composite end point of admission to ICU, NIV or death.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialEudraCT number: 2020-001934-37Funding StatementNo specific fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comite de Etica en Investigacion con Medicamentos de CantabriaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequest from authors